Mylan Launches Generic Version of Sandostatin

Mylan Inc. MYL today announced that its subsidiary Bioniche Pharma has launched Octreotide Acetate Injection USP, pre-filled syringes, the generic version of Novartis' Sandostatin®, a treatment for a rare hormonal disorder called acromegaly. Octreotide Acetate Injection is also used to suppress or inhibit severe diarrhea associated with metastatic carcinoid tumors and vasoactive intestinal peptide tumors. Mylan Institutional President Matt Erick said: "This approval is particularly important because it is the first and only PFS for this product – brand or generic – providing hospitals and clinics access to a preferred presentation that offers ease, accuracy and convenience of dosing. The addition of Octreotide Acetate Injection as Mylan Institutional's first PFS is a critical next step in expanding our already diverse portfolio of injectable products."